Trials / Completed

CompletedNCT00605644

Study Evaluating MOA-728 Oral for the Treatment of OIBD in Subjects With Chronic Non-Malignant Pain

A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study of Oral MOA-728 for the Treatment of Opioid-Induced Bowel Dysfunction in Subjects With Chronic Nonmalignant Pain

Status: Completed
Phase: Phase 2
Study type: Interventional
Enrollment: 128 (actual)

Sponsor: Bausch Health Americas, Inc. · Industry
Sex: All
Age: 18 Years
Healthy volunteers: Not accepted

Summary

The primary purpose of this study is to evaluate the safety and dose-response relationship of N-methylnaltrexone bromide (MOA-728) by observing spontaneous bowel movements in subjects administered MOA-728 who have chronic pain that is not due to cancer, and who have opioid-induced bowel dysfunction (OIBD).

Conditions

Constipation

Interventions

Type	Name	Description
DRUG	MOA-728	Oral Capsules
DRUG	Placebo	Placebo

Timeline

Start date: 2008-01-01
Primary completion: 2008-05-01
Completion: 2008-05-01
First posted: 2008-01-31
Last updated: 2020-08-20
Results posted: 2020-08-20

Source: ClinicalTrials.gov record NCT00605644. Inclusion in this directory is not an endorsement.